Pulmonary embolism: impact of right ventricular dysfunction.

Area of Science:

• Cardiology
• Pulmonary Medicine
• Critical Care Medicine

Background:

• The optimal management of acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and normal blood pressure remains controversial.
• Thrombolytic therapy is debated for normotensive PE patients with RV dysfunction.
• Recent studies have enhanced understanding of subclinical RV dysfunction and risk stratification in PE.

Purpose of the Study:

• To review current understanding of RV dysfunction in normotensive PE.
• To evaluate the role of risk stratification algorithms and biomarkers in identifying high-risk PE patients.
• To discuss the potential benefits and ongoing debate surrounding thrombolytic treatment in this patient population.

Main Methods:

• Meta-analysis of studies on echocardiographically diagnosed RV dysfunction in normotensive PE.
• Review of retrospective studies utilizing multidetector-row chest computed tomography (MDCT) for RV assessment.
• Analysis of recent data on biomarker testing (troponin) and echocardiography in PE risk stratification.

Main Results:

• Echocardiographic RV dysfunction is an independent predictor of early mortality in normotensive PE.
• MDCT may provide similar prognostic information to echocardiography.
• Biomarker testing combined with echocardiography offers an efficient strategy for outcome prediction in PE.

Conclusions:

• Novel risk stratification algorithms can identify PE patients who may benefit from early thrombolysis.
• These algorithms provide a foundation for future international studies to resolve the long-standing debate on thrombolysis benefits.
• Further research is needed to definitively establish the role of thrombolysis in normotensive PE with RV dysfunction.